Testing Status of Interferon AD + 3'-azido-3'-deoxythymidine (AIDS Initiative) M890012

 

CASRN: INTAZTCOMB

Formula: N/F

Secondary:

  • 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
  • 30516-87-1 - AZT transplacental carcinogenesis study
  • INTERFERONAD - Interferon AD (AIDS Initiative)

Known Uses

Used in the experimental treatment of AIDS

Short-Term Toxicity

  • 4 weeks (Subcutaneous Injection and Gavage)  (C89006)  Completed 
    • Mice: B6C3F1
    • Dose: DUAL ROUTES: IFN-AD (SC/IJ): 500, 5000, 50000, OR 500000 UNITS/MOUSE/DAY AZT (GAVAGE): 0, 500, OR 1000 MG/KG.

Long-Term Carcinogenicity

  • 2 years (Subcutaneous Injection and Gavage)  (C89006)  Report Complete 
    • TR-469 (NIH Number: 99-3959)  (Peer Review Approval 12/11/1996A )
      Toxicology and Carcinogenesis Studies of AZT (CASRN 30516-87-1) and AZT/ a-Interferon A/D B6C3F1 Mice (Gavage Studies)
    • Mice: B6C3F1
    • Dose: DUAL ROUTES WITH BOTH COMPOUNDS: AZT: 0, 30, 60, OR 120 (GAV) MG/KG; IFN: 500 OR 5000 UNITS 3X/WEEK.